Forsta AP Fonden lowered its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 6.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 384,351 shares of the company’s stock after selling 26,257 shares during the quarter. Eli Lilly And Co makes up 1.2% of Forsta AP Fonden’s portfolio, making the stock its 22nd biggest holding. Forsta AP Fonden’s holdings in Eli Lilly And Co were worth $32,797,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the stock. Victory Capital Management Inc. boosted its stake in Eli Lilly And Co by 3.8% during the first quarter. Victory Capital Management Inc. now owns 19,693 shares of the company’s stock valued at $1,524,000 after buying an additional 727 shares during the last quarter. Chicago Equity Partners LLC boosted its stake in Eli Lilly And Co by 37.8% during the first quarter. Chicago Equity Partners LLC now owns 18,105 shares of the company’s stock valued at $1,401,000 after buying an additional 4,965 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in Eli Lilly And Co by 147.8% during the first quarter. Thrivent Financial for Lutherans now owns 346,594 shares of the company’s stock valued at $26,817,000 after buying an additional 206,748 shares during the last quarter. Timber Hill LLC bought a new position in Eli Lilly And Co during the first quarter valued at approximately $258,000. Finally, Intact Investment Management Inc. bought a new position in Eli Lilly And Co during the first quarter valued at approximately $217,000. Hedge funds and other institutional investors own 76.56% of the company’s stock.

Eli Lilly And Co stock opened at $115.02 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $115.25 billion, a PE ratio of 26.87, a price-to-earnings-growth ratio of 1.88 and a beta of 0.29. Eli Lilly And Co has a 1-year low of $73.69 and a 1-year high of $115.68.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 24th. The company reported $1.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.20. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The firm had revenue of $6.36 billion during the quarter, compared to analysts’ expectations of $6.05 billion. During the same quarter last year, the firm earned $1.11 EPS. The business’s quarterly revenue was up 9.1% on a year-over-year basis. As a group, equities research analysts expect that Eli Lilly And Co will post 5.47 EPS for the current fiscal year.

In other news, SVP Alfonso G. Zulueta sold 6,000 shares of the business’s stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $106.31, for a total value of $637,860.00. Following the completion of the transaction, the senior vice president now owns 55,224 shares of the company’s stock, valued at approximately $5,870,863.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Alfonso G. Zulueta sold 7,000 shares of the business’s stock in a transaction dated Thursday, October 4th. The shares were sold at an average price of $114.64, for a total value of $802,480.00. Following the completion of the transaction, the senior vice president now directly owns 45,224 shares of the company’s stock, valued at approximately $5,184,479.36. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,770,943 shares of company stock valued at $178,470,135. 0.11% of the stock is currently owned by insiders.

Several equities research analysts have recently issued reports on the company. BMO Capital Markets raised Eli Lilly And Co from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $107.00 to $130.00 in a research note on Thursday. JPMorgan Chase & Co. set a $123.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a research note on Friday. SunTrust Banks raised their price objective on Eli Lilly And Co from $105.00 to $123.00 and gave the company a “buy” rating in a research note on Monday, October 1st. ValuEngine lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Tuesday, October 2nd. Finally, Zacks Investment Research lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Friday, September 28th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $106.06.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Conference Calls and Individual Investors

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.